SK26495A3 - N-substituted acridines and inhibitors of cytochrome p450 and methods of their use - Google Patents
N-substituted acridines and inhibitors of cytochrome p450 and methods of their use Download PDFInfo
- Publication number
- SK26495A3 SK26495A3 SK264-95A SK26495A SK26495A3 SK 26495 A3 SK26495 A3 SK 26495A3 SK 26495 A SK26495 A SK 26495A SK 26495 A3 SK26495 A3 SK 26495A3
- Authority
- SK
- Slovakia
- Prior art keywords
- inhibitor
- formula
- tacrine
- acridine
- oxidase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Lubricants (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/943,323 US5422350A (en) | 1992-09-10 | 1992-09-10 | Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use |
US08/100,917 US5466696A (en) | 1992-09-10 | 1993-08-09 | Tacrine and cytochrome P450 oxidase inhibitors and methods of use |
PCT/US1993/008459 WO1994005296A2 (en) | 1992-09-10 | 1993-09-08 | Use of cytochrome p450 inhibitors for inhibiting the metabolism of nitrogen substituted acridine |
Publications (1)
Publication Number | Publication Date |
---|---|
SK26495A3 true SK26495A3 (en) | 1996-05-08 |
Family
ID=26797688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK264-95A SK26495A3 (en) | 1992-09-10 | 1993-09-08 | N-substituted acridines and inhibitors of cytochrome p450 and methods of their use |
Country Status (18)
Country | Link |
---|---|
US (1) | US5466696A (de) |
EP (1) | EP0659082B1 (de) |
JP (1) | JPH08501105A (de) |
KR (1) | KR950703339A (de) |
AT (1) | ATE212845T1 (de) |
AU (1) | AU669586B2 (de) |
CA (1) | CA2141425A1 (de) |
CZ (1) | CZ48095A3 (de) |
DE (1) | DE69331546T2 (de) |
DK (1) | DK0659082T3 (de) |
ES (1) | ES2171419T3 (de) |
FI (1) | FI951024A (de) |
HU (1) | HU217845B (de) |
NO (1) | NO307955B1 (de) |
NZ (1) | NZ256940A (de) |
PT (1) | PT659082E (de) |
SK (1) | SK26495A3 (de) |
WO (1) | WO1994005296A2 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5567592A (en) * | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
US5665386A (en) * | 1995-06-07 | 1997-09-09 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
CA2224227A1 (en) * | 1995-06-07 | 1996-12-19 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
US5716928A (en) * | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
US6218383B1 (en) * | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
JP5143988B2 (ja) | 1999-07-22 | 2013-02-13 | オルガノジェネシス インク. | 単離された肝細胞の機能を増強させるためのイン・ビボ誘導 |
AU2002367057B2 (en) * | 2001-12-21 | 2007-01-11 | Organogenesis Inc. | Chamber with adjustable volume for cell culture and organ assist |
AU2003270446A1 (en) * | 2002-09-25 | 2004-04-19 | The Board Of Trustees Of The University Of Illinois | Method and composition for treating alzheimer's disease and dementias of vascular origin |
US7583551B2 (en) | 2004-03-10 | 2009-09-01 | Micron Technology, Inc. | Power management control and controlling memory refresh operations |
DE102005044815A1 (de) * | 2005-09-20 | 2007-03-22 | Sanofi-Aventis Deutschland Gmbh | Verwendung von Inhibitoren des Na+/H+ Austauschers, Subtyp 5 (NHE5) zur Gedächtnisverbesserung |
WO2008153722A1 (en) * | 2007-05-22 | 2008-12-18 | The Board Of Regents Of The University Of Texas System | Post-translational regulation of catalytic activities of cytochrome p450 46a1 and uses thereof |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2233970A (en) * | 1941-03-04 | Quinoline compound and process of | ||
DE1643240A1 (de) * | 1966-09-16 | 1971-06-24 | Boehringer Sohn Ingelheim | Verfahren zur Herstellung neuer racemischer oder optisch aktiver 1-Phenoxy-2-aminoalkane |
GB1338169A (en) * | 1971-03-09 | 1973-11-21 | Smith Kline French Lab | Ureas thioureas and guanidines |
SU429813A1 (ru) * | 1971-08-20 | 1974-05-30 | Способ лечения туберкулеза легких | |
AR223983A1 (es) * | 1978-08-25 | 1981-10-15 | Dainippon Pharmaceutical Co | Un procedimiento para-preparar derivados de acido 6-halogeno-4-oxo-7-(1-piperazinil)-1,8-naftiridin-3-carboxilico |
SU789112A1 (ru) * | 1979-04-12 | 1980-12-23 | Научно-исследовательский институт экспериментальной и клинической медицины | Способ лечени экстрасистолической аритмии у детей |
SU827081A1 (ru) * | 1979-06-05 | 1981-05-07 | Донецкий Медицинский Институт Им.M.Горького | Способ лечени вазомоторных головныхбОлЕй |
GB2091249A (en) * | 1980-12-23 | 1982-07-28 | Fordonal Sa | Xanthine derivatives |
SU1049065A1 (ru) * | 1981-01-09 | 1983-10-23 | Andronova Liliya Z | Способ лечени заикани |
JPS57134482A (en) * | 1981-02-13 | 1982-08-19 | Dainippon Pharmaceut Co Ltd | 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8- naphthyridine-3-carboxylic acid-3/2 hydrate and its preparation |
SU1156700A1 (ru) * | 1982-01-19 | 1985-05-23 | Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср | Способ лечени неврозов |
SU1210789A1 (ru) * | 1983-07-21 | 1986-02-15 | Военно-Медицинская Ордена Ленина Краснознаменная Академия Им.С.М.Кирова | Способ диагностики функционального нарушени желудочной секреции |
SU1196002A1 (ru) * | 1984-06-28 | 1985-12-07 | Запорожский государственный институт усовершенствования врачей им.М.Горького | Способ лечени хронического сальпингоофорита |
US4835275A (en) * | 1984-10-25 | 1989-05-30 | Hoechst-Roussel Pharmaceuticals, Inc. | Method of preparing 9-amino-1,2,3,4,-tetrahydroacridin-1-ones and related compounds |
US4695573A (en) * | 1984-10-25 | 1987-09-22 | Hoechst-Roussel Pharmaceuticals Inc. | 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds |
US4631286A (en) * | 1984-10-25 | 1986-12-23 | Hoechst-Roussel Pharmaceuticals Inc. | 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds |
US4754050A (en) * | 1984-10-25 | 1988-06-28 | Hoechst-Roussel Pharmaceuticals, Inc. | 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds |
EP0179383B1 (de) * | 1984-10-25 | 1991-05-29 | Hoechst-Roussel Pharmaceuticals Incorporated | 9-Amino-1,2,3,4-tetrahydroacridin-1-ol und verwandte Verbindungen, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel |
SU1537252A1 (ru) * | 1985-03-28 | 1990-01-23 | Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср | Способ лечени парестезий полости рта |
SU1416125A1 (ru) * | 1986-02-21 | 1988-08-15 | Одесский Научно-Исследовательский Институт Курортологии | Способ лечени заболеваний суставов |
SU1389050A1 (ru) * | 1986-07-28 | 1990-08-30 | Niiex Meditsiny An Sssr | Cпocoб лeчehия aлkoгoлизma |
US4816456A (en) * | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
WO1989002739A1 (en) * | 1987-10-05 | 1989-04-06 | Pfizer Inc. | 4-aminopyridine derivatives |
US5019395A (en) * | 1988-03-08 | 1991-05-28 | Warner-Lambert Company | Compositions with enhanced penetration |
ATE89553T1 (de) * | 1988-11-16 | 1993-06-15 | Hoechst Roussel Pharma | Hydroxy-1,2,3,4-tetrahydroaminoacridine, verfahren fuer ihre herstellung und ihre verwendung als arzneimittel. |
GB8827704D0 (en) * | 1988-11-28 | 1988-12-29 | Fujisawa Pharmaceutical Co | New acridine derivatives & processes for their production |
US4999430A (en) * | 1989-07-31 | 1991-03-12 | Warner-Lambert Company | Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine |
-
1993
- 1993-08-09 US US08/100,917 patent/US5466696A/en not_active Expired - Fee Related
- 1993-09-08 DK DK93923110T patent/DK0659082T3/da active
- 1993-09-08 EP EP93923110A patent/EP0659082B1/de not_active Expired - Lifetime
- 1993-09-08 ES ES93923110T patent/ES2171419T3/es not_active Expired - Lifetime
- 1993-09-08 NZ NZ256940A patent/NZ256940A/en unknown
- 1993-09-08 DE DE69331546T patent/DE69331546T2/de not_active Expired - Fee Related
- 1993-09-08 CA CA002141425A patent/CA2141425A1/en not_active Abandoned
- 1993-09-08 CZ CZ95480A patent/CZ48095A3/cs unknown
- 1993-09-08 AU AU52905/93A patent/AU669586B2/en not_active Ceased
- 1993-09-08 WO PCT/US1993/008459 patent/WO1994005296A2/en not_active Application Discontinuation
- 1993-09-08 HU HU9500704A patent/HU217845B/hu not_active IP Right Cessation
- 1993-09-08 KR KR1019950700943A patent/KR950703339A/ko not_active Application Discontinuation
- 1993-09-08 PT PT93923110T patent/PT659082E/pt unknown
- 1993-09-08 JP JP6507526A patent/JPH08501105A/ja not_active Ceased
- 1993-09-08 AT AT93923110T patent/ATE212845T1/de not_active IP Right Cessation
- 1993-09-08 SK SK264-95A patent/SK26495A3/sk unknown
-
1995
- 1995-03-06 FI FI951024A patent/FI951024A/fi unknown
- 1995-03-09 NO NO950909A patent/NO307955B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
ATE212845T1 (de) | 2002-02-15 |
CZ48095A3 (en) | 1995-12-13 |
HUT70979A (en) | 1995-11-28 |
WO1994005296A3 (en) | 1994-04-28 |
WO1994005296A2 (en) | 1994-03-17 |
NO950909D0 (no) | 1995-03-09 |
AU5290593A (en) | 1994-03-29 |
NZ256940A (en) | 1996-03-26 |
FI951024A0 (fi) | 1995-03-06 |
CA2141425A1 (en) | 1994-03-17 |
DK0659082T3 (da) | 2002-06-17 |
DE69331546T2 (de) | 2002-10-31 |
NO307955B1 (no) | 2000-06-26 |
NO950909L (no) | 1995-03-09 |
EP0659082A1 (de) | 1995-06-28 |
AU669586B2 (en) | 1996-06-13 |
US5466696A (en) | 1995-11-14 |
DE69331546D1 (de) | 2002-03-21 |
JPH08501105A (ja) | 1996-02-06 |
HU217845B (hu) | 2000-04-28 |
KR950703339A (ko) | 1995-09-20 |
FI951024A (fi) | 1995-03-06 |
PT659082E (pt) | 2002-07-31 |
HU9500704D0 (en) | 1995-04-28 |
ES2171419T3 (es) | 2002-09-16 |
EP0659082B1 (de) | 2002-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sharma et al. | Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird's eye view | |
Pichard et al. | Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. | |
Jeppesen et al. | Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine | |
Murray | Role of CYP pharmacogenetics and drug‐drug interactions in the efficacy and safety of atypical and other antipsychotic agents | |
Andersson | Omeprazole drug interaction studies | |
Grace et al. | Metabolism of β-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450 | |
CN107921035B (zh) | 高苯丙氨酸血症及其治疗 | |
Kharasch et al. | Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity | |
US5422350A (en) | Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use | |
CA2523808A1 (en) | Pyrrole compounds and uses thereof | |
SK26495A3 (en) | N-substituted acridines and inhibitors of cytochrome p450 and methods of their use | |
US20240000765A1 (en) | Combination treatment of liver disorders | |
Maddaford et al. | Advancements in the development of nitric oxide synthase inhibitors | |
EP1616576A1 (de) | Spezifischer nad(p)h oxidase-hemmer | |
Labbe et al. | Role of specific cytochrome P450 enzymes in the N-oxidation of the antiarrhythmic agent mexiletine | |
US7754767B2 (en) | Method for treatment of premature ejaculation in humans | |
CN115003289A (zh) | 大麻二酚和/或考比司他联合药物疗法 | |
AU742628B2 (en) | Methods for regulating nicotine metabolism | |
JP3276762B2 (ja) | イソキノリン誘導体を含有する医薬組成物 | |
US20050032844A1 (en) | Methods for regulating nicotine metabolism | |
NZ280680A (en) | Use of a P450 1A inhibitor to inhibit the enzymatic metabolism of a nitrogen substituted acridine derivative | |
Coluccia et al. | Indoleamine 2, 3-dioxygenase | |
Luscombe et al. | Progress in Medicinal Chemistry. 30 | |
Baune et al. | In vitro effects of racemates, separate enantiomers and major metabolites of mefloquine and halofantrine on metoprolol biotransformation by rat liver microsomes | |
Konishi et al. | Moricizine, an antiarrhythmic agent, as a potent inhibitor of hepatic microsomal CYP1A |